GlaxoSmithKline hunts agency to promote weight-loss drug in Europe

GlaxoSmithKline has kicked off a search for Alli - a US over-the-counter weight-loss drug - as it looks to launch the product across Europe.

GSK has approached a number of London agencies, with both roster and non-roster agencies being asked to tender.

The brief comprises digital and DM elements. Much of the initial work will be adapted from US advertising until such time as plans to launch the drug in Europe are given the go-ahead.

GlaxoSmithKline has already made inroads to get the product approved for sale in Europe, though under a different name. Last month, the European medicines regulator agreed to review a proposal for the drug's over- the-counter sale and respond next year.

This summer, Alli became the first weight-loss drug approved by the United States' Food and Drug Administration for sale over the counter. In the first five weeks after its launch, sales were more than £77 million.

GlaxoSmithKline did not return calls.

Become a member of Campaign

Get the very latest news and insight from Campaign with unrestricted access to, plus get exclusive discounts to Campaign events.

Become a member

What is Campaign AI?

Our new premium service offering bespoke monitoring reports for your company.

Find out more

Looking for a new job?

Get the latest creative jobs in advertising, media, marketing and digital delivered directly to your inbox each day.

Create an alert now

Partner content